Centralized or decentralized manufacturing? Key business model considerations for cell therapies
The choice of manufacturing strategy for cell-based therapeutics is one that is best made early in product development. Expense and delay may result from any additional bridging studies following changes to manufacturing process design late in development. The chosen strategy will be strongly influe...
Saved in:
| Main Author: | |
|---|---|
| Format: | Default Article |
| Published: |
2016
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2134/20841 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|